Skip to main
OKUR
OKUR logo

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc. demonstrated a positive trend in its financial performance for Q2 2025, with a net loss per share of $1.14, which is an improvement compared to the initial estimate of $1.22. The successful tolerance profile of OKI-219 across all dose levels, with no instances of hyperglycemia and only Grade 1 treatment-related adverse events, indicates the potential for favorable clinical outcomes. This combination of managing costs effectively while advancing a well-tolerated treatment position OnKure Therapeutics favorably within the clinical-stage biopharmaceutical industry.

Bears say

OnKure Therapeutics is projecting a full-year 2025 net loss of $4.56 per share, slightly improving from a previous estimate of $4.75 per share. The company faces significant risks, including potential negative clinical results for its lead asset, OKI-219, delays in advancing pipeline candidates, and challenges in obtaining timely regulatory approvals. Furthermore, competitive pressures from other mutant-selective PI3Kα inhibitors and long-term dilution concerns further contribute to a negative outlook for the company's financial health.

OKUR has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Buy based on their latest research and market trends.

According to 4 analysts, OKUR has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.